Increased morbidity and mortality of hepatocellular carcinoma patients in lower cost of living areas

Abstract

BACKGROUND The incidence and mortality rates of hepatocellular carcinoma (HCC) are increasing in the United States. However, the increases in different racial and socioeconomic groups have not been homogeneous. Access to healthcare based on socioeconomic status and cost of living index (COLI), especially in HCC management, is under characterized. AIM The aim was to investigate the relationship between the COLI and tumor characteristics, treatment modalities, and survival of HCC patients in the United States. METHODS A retrospective study of the Surveillance, Epidemiology, and End Results (SEER) database was conducted to identify patients with HCC between 2007 and 2015 using site code C22.0 and the International Classification of Disease for Oncology, 3rd edition (ICD-O-3) codes 8170-8173, and 8175. Cases of fibrolamellar HCC were excluded. Variables collected included demographics, COLI, insurance status, marital status, stage, treatment, tumor size, and survival data. Interquartile ranges for COLI were obtained. Based on the COLI, the study population was separated into four groups: COLI ≤ 901, 902-1044, 1045-1169, ≥ 1070. The χ 2 test was used to compare categorical variables, and the Kruskal-Wallis test was used to compare continuous variables without normal distributions. Survival was estimated by the Kaplan-Meier method. We defined P < 0.05 as statistically significant. RESULTS We identified 47,894 patients with HCC. Patients from the highest COLI areas were older (63 vs 61 years of age), more likely to be married (52.8% vs 48.0%), female (23.7% vs 21.1%), and of Asian and Pacific Islander descent (32.7% vs 4.8%). The patients were more likely to have stage I disease (34.2% vs 32.6%), tumor size ≤ 30 mm (27.1% vs 23.1%), received locoregional therapy (11.5% vs 6.1%), and undergone surgical resection (10.7% vs 7.0%) when compared with the lowest quartile. The majority of patients with higher COLIs resided in California, Connecticut, Hawaii, and New Jersey. Patients with lower COLIs were more likely to be uninsured (5.7% vs 3.4%), have stage IV disease (15.2% vs 13%), and have received a liver transplant (6.6% vs 4.4%) compared with patients from with the highest COLI. Median survival increased with COLI from 8 (95%CI: 7-8), to 10 (10-11), 11 (11-12), and 14 (14-15) mo ( P < 0.001) among patients with COLIs of ≤ 901, 902-1044, 1045-1169, ≥ 1070, respectively. After stratifying by year, a survival trend was present: 2007-2009, 2010-2012, and 2013-2015. CONCLUSION Our study suggested that there w...

The Pyroptosis-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Immunotherapeutic Efficiency in Hepatocellular Carcinoma

“…Because of its characteristics of rapid tumor progression, recurrence, metastasis, and resistance to treatment, its prognosis is usually very poor. HCC, as a leading cause of cancer-related mortality worldwide, has a significant influence on the quality of life of HCC and also incurs huge economic costs ( Jemal et al, 2011 ; Sempokuya et al, 2021 ). Although many recent efforts have been made to treat HCC, the long-term prognosis of HCC patients remains very poor.…”

Assessing the Impact of Socioeconomic Status on Incidental Lung Nodules at an Urban Safety Net Hospital

“…COLI is a relative marker of living expenses compared to United States estimates, with values above 100 conferring higher than average costs of living. COLI has not been extensively studied in relation to LCS or lung nodule outcomes; however, prior studies in individuals with hepatocellular cancer found that those with lower COLI presented with more advanced cancers, while higher COLI was associated with improved survival [29]. We found a weak association between individuals from lower COLI areas and smaller nodules < 6 mm (OR 0.933, p 0.056), while higher COLI areas were weakly associated with nodules between 6-8 mm (PR 1.084, p 0.048), the signi cance of which is undetermined.…”

Clinical Informatics Approaches to Understand and Address Cancer Disparities

“…Race has also been shown to influence treatment recommendations, with Black patients less likely to be offered surgical resection for certain skull-base tumors [22]. Furthermore, excess cancer mortality has been reported in some U.S. minority groups across cancer types [23][24][25][26][27][28][29][30][31][32]. As an example, based on SEER analysis (2000-2017) the epidemiological profile of metastatic bladder cancer suggests Black females are more likely to die from this disease than any other group [33].…”